Gastroenterology

www.gastrojournal.org Vol. 154, No. 5 April 2018

TABLE OF CONTENTS

Contents

ON THE COVER

See article by Roy et al on page 1405 for further information.

GASTROENTEROLOGY'S DIAMOND ANNIVERSARY: 1943–2018

1209 **Contributions From *Gastroenterology*: Acid Peptic Disorders, Barrett's Esophagus and Eosinophilic Esophagitis**
R. F. Souza, J. H. Rubenstein, J. Y. Kao, and I. Hirano

COVERING THE COVER

1215 *A. T. Chan and C. S. Williams*

COMMENTARY

1217 **New Eosinophilic Esophagitis Concepts Call for Change in Proton Pump Inhibitor Management Before Diagnostic Endoscopy**
E. Odiase, A. Schwartz, R. F. Souza, J. Martin, V. Konda, and S. J. Spechler

MEETING SUMMARY

e1 **Meeting Report: AGA Biosimilars Roundtable**
C. W. Howden and G. R. Lichtenstein

MENTORING, EDUCATION, AND TRAINING CORNER

1222 **How to Perform a High-Quality Examination in Patients With Barrett's Esophagus**
M. A. Everson, K. Ragunath, P. Bhandari, L. Lovat, and R. Haidry

V Video CGH Related article in CGH Hot Papers From New Investigators

CME CME quiz E Editorial accompanies this article WWW Additional online content available COV Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi monthly in January and May) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2018 US subscription rates: individual, $711.00; student and resident, $271.00. Outside of the U.S. and possessions: individual, $968.00; student and resident, $562.00; surface delivery, no additional charge; air mail delivery, add $78.00. Prices subject to change without notice.

TABLE OF CONTENTS

EDITORIALS

1227 **Getting into a TIF(F) Over Fundoplication**
P. O. Katz and D. A. Katzka
See Richter JE et al on page 1298.

1229 **Inhibiting Cytokinesis in the Liver: A New Way to Reduce Tumor Development**
C. Desdouets and M. A. Avila
See Zhang S et al on page 1421.

1231 **YAPping About Glutaminolysis in Hepatic Fibrosis**
L. D. Harvey and S. Y. Chan
See Du K et al on page 1465.

GASTROENTEROLOGY IN MOTION

1234 **Virtual Endoscopy Based on 3-Dimensional Reconstruction of Histopathology Features of Endoscopic Resection Specimens**
R. Schmitz, J. Krause, T. Krech, and T. Rösch

CLINICAL CHALLENGES AND IMAGES IN GI

1237 **Rodeo, Anyone?**
A. Dolganiuc, P. V. Draganov, and A. Schlachterman

1239 **A Surprising Granulomatous Cheilitis**
C. Charpentier, D. Kottler, C. Fite, A.-L. Pelletier, L. Deschamps, and V. Descamps

1241 **Diffuse Small Intestine Erosions and Ulcers in an Immunocompromised Host**
O. Aseem, D. S. Childs, and C. G. Loftus

1244 **An Unusual Colon Cystic Tumor**
M.-H. Hsu, Y.-J. Chen, and W.-L. Wang

ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GI

For a full list, please see the table of contents online at www.gastrojournal.org.

PRACTICAL TEACHING CASE

1246 **Two Types of Gastric Cancer Caused by the Same Underlying Condition**
N. Rustgi, S. G. Shroff, and B. W. Katona

AGA CLINICAL PRACTICE UPDATE: EXPERT REVIEW

1249 **Best Practice Update: Incorporating Psychogastroenterology Into Management of Digestive Disorders**
L. Keefer, O. S. Palsson, and J. E. Pandolfino

REVIEWS AND PERSPECTIVES

Reviews in Basic and Clinical Gastroenterology and Hepatology

1258 **Biotechnology Challenges to In Vitro Maturation of Hepatic Stem Cells**
C. Chen, A. Soto-Gutierrez, P. M. Baptista, and B. Spee

ORIGINAL RESEARCH

Full Reports

Clinical—Alimentary Tract

1273 Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants
J. Dong, M. F. Buas, P. Gharahkhani, B. J. Kendall, L. Onstad, S. Zhao, L. A. Anderson, A. H. Wu, W. Ye, N. C. Bird, L. Bernstein, W.-H. Chow, M. D. Gammon, G. Liu, C. Caldas, P. D. Pharoah, H. A. Risch, P. G. Iyer, B. J. Reid, L. J. Hardie, J. Lagergren, N. J. Shaheen, D. A. Corley, R. C. Fitzgerald, Stomach and Oesophageal Cancer Study (SOCS) consortium, D. C. Whiteman, T. L. Vaughan, and A. P. Thrift

Prediction models that combine epidemiologic and genetic data for Barrett's esophagus and esophageal adenocarcinoma may more accurately identify patients at higher levels of risk to allow personalization of therapy.

1282 Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia
S. Parasa, S. Vennalaganti, S. Gaddam, P. Vennalaganti, P. Young, N. Gupta, P. Thota, B. Cash, S. Mathur, R. Sampliner, F. Moawad, D. Lieberman, A. Bansal, K. F. Kennedy, J. Vargo, G. Falk, M. Spaander, M. Bruno, and P. Sharma

A new scoring system identified patients with Barrett's esophagus at low, intermediate, or high risk for developing high-grade dysplasia (HGD) and esophageal adenocarcinoma.

1290 No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication
L. H. Nguyen, P. Lochhead, A. D. Joshi, Y. Cao, W. Ma, H. Khalili, E. B. Rimm, K. M. Rexrode, and A. T. Chan

Among participants in two large prospective cohorts, proton pump inhibitor use was not associated with risk for incident ischemic stroke after adjusting for clinical indications of use.

1298 Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis
J. E. Richter, A. Kumar, S. Lipka, B. Miladinovic, and V. Velanovich

See editorial on page 1227.
When compared with laparoscopic Nissen fundoplication (LNF), transoral incisionless fundoplication cannot be recommended based on current evidence as a long-term alternative to PPIs or LNF for treatment of GERD.

1309 Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis
R. Khera, A. Pandey, A. K. Chandar, M. H. Murad, L. J. Prokop, I. J. Neeland, J. D. Berry, M. Camilleri, and S. Singh

Though several pharmacological weight loss agents have been approved, they only exert a modest impact on cardiometabolic risk profile in obese and overweight adults, even one year after therapy. Their impact on modifying long-term cardiovascular outcomes merits detailed evaluation.

1320 Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases
M. Šimurina, N. de Haan, F. Vučković, N. A. Kennedy, J. Štambuk, D. Falck, I. Trbojević-Akmačić, F. Clerc, G. Razdorov, A. Khon, A. Latiano, R. D'Incà, S. Danese, S. Targan, C. Landers, M. Dubinsky, The Inflammatory Bowel Disease Biomarkers Consortium, D. P. B. McGovern, V. Annese, M. Wuhrer, and G. Lauc

This large multicentric study of >3,400 IBD patients and controls demonstrated potential for the IgG glycome to serve as a novel biomarker for stratification of IBD patients within a precision medicine treatment strategy.

1334 **Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease**
J. Panés, D. García-Olmo, G. Van Assche, J. F. Colombel, W. Reinisch, D. C. Baumgart, A. Dignass, M. Nachury, M. Ferrante, L. Kazemi-Shirazi, J. C. Grimaud, F. de la Portilla, E. Goldin, M. P. Richard, M. C. Diez, I. Tagarro, A. Leselbaum, and S. Danese, for the ADMIRE CD Study Group Collaborators

The results of this study suggest that stem cell therapy is an effective, durable, and safe treatment for healing complex perianal fistulas in patients with Crohn's disease.

1343 **Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease**
G. D'Haens, S. Vermeire, G. Lambrecht, F. Baert, P. Bossuyt, B. Pariente, A. Buisson, Y. Bouhnik, J. Filippi, J. vander Woude, P. Van Hootegem, J. Moreau, E. Louis, D. Franchimont, M. De Vos, F. Mana, L. Peyrin-Biroulet, H. Brixi, M. Allez, P. Caenepeel, A. Aubourg, B. Oldenburg, M. Pierik, A. Gils, S. Chevret, and D. Laharie, on behalf the GETAID

Increasing doses of infliximab based on a combination of symptoms and serum drug concentrations does not affect corticosteroid-free clinical remission compared to a strategy based on symptoms alone.

1352 **Increasing Rates of Surgery for Patients With Nonmalignant Colorectal Polyps in the United States**
A. F. Peery, K. S. Cools, P. D. Strassle, S. K. McGill, S. D. Crockett, A. Barker, M. Koruda, and I. S. Grimm

In a large, nationally representative sample, the authors found that surgery for non-malignant colorectal polyps is common and has significantly increased over the last 14 years.

Clinical—Liver

1361 **Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction**
X. Verhelst, A. Geerts, I. Jochmans, D. Vanderschaeghe, A. Paradissis, A. Vanlander, F. Berrevoet, G. Dahlqvist, F. Nevens, J. Pirenne, X. Rogiers, N. Callewaert, R. I. Troisi, and H. Van Vlierberghe

Analyzing the glycomic profile of perfusion fluid in which the liver is transported from donor to recipient can help predict the occurrence of primary non-function.

1369 **Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease**
M. Thiele, B. S. Madsen, J. F. Hansen, S. Detlefsen, S. Antonsen, and A. Krag

In patients with alcoholic liver disease, a blood-based biomarker test, Enhanced Liver Fibrosis test, and FibroTest have excellent accuracy for diagnosing advanced liver fibrosis, the precursor of cirrhosis. However, liver stiffness with ultrasound elastography remains the most accurate marker.

Clinical—Pancreas

1380 **Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies**
N. Khalaf, C. Yuan, T. Hamada, Y. Cao, A. Babic, V. Morales-Oyarvide, P. Kraft, K. Ng, E. Giovannucci, S. Ogino, M. Stampfer, B. B. Cochrane, J. E. Manson, C. B. Clish, A. T. Chan, C. S. Fuchs, and B. M. Wolpin

Regular aspirin or non-aspirin NSAID use was not associated with subsequent risk of pancreatic cancer.

Basic and Translational—Alimentary Tract

1391 ***Helicobacter pylori* Depletes Cholesterol in Gastric Glands to Prevent Interferon Gamma Signaling and Escape the Inflammatory Response**
P. Morey, L. Pfannkuch, E. Pang, F. Boccellato, M. Sigal, A. Imai-Matsushima, V. Dyer, M. Koch, H.-J. Mollenkopf, P. Schlaermann, and T. F. Meyer

Helicobacter pylori colonizes the gastric mucosa for decades. The authors identified a key step in the host immune response that is inhibited by the bacteria. This is mediated through extraction of cholesterol from host cells, which leads to failure of IFN receptor assembly and bactericidal responses.

1405 **Villin-1 and Gelsolin Regulate Changes in Actin Dynamics That Affect Cell Survival Signaling Pathways and Intestinal Inflammation**
S. Roy, A. Esmaeilniakooshkghazi, S. Patnaik, Y. Wang, S. P. George, A. Ahrorov, J. K. Hou, A. J. Herron, H. Sesaki, and S. Khurana

These studies demonstrate the role of two actin binding proteins, villin-1 and gelsolin in stress signaling and their contribution to the pathogenesis of Crohn's disease.

Basic and Translational—Liver

1421 **Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration**
S. Zhang, L. H. Nguyen, K. Zhou, H.-C. Tu, A. Sehgal, I. Nassour, L. Li, P. Gopal, J. Goodman, A. G. Singal, A. Yopp, Y. Zhang, D. J. Siegwart, and H. Zhu

See editorial on page 1229.
Cytokinesis inhibition through suppression of Anillin Actin Binding Protein in the liver can effectively suppress tumor development while sparing normal liver function and regeneration.

1435 **Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape Variants**
J. M. Gottwein, L. V. Pham, L. S. Mikkelsen, L. Ghanem, S. Ramirez, T. K. H. Scheel, T. H. R. Carlsen, and J. Bukh

Among 7 clinically relevant hepatitis C virus NS5A inhibitors, pibrentasvir and velpatasvir exerted pangenotypic effects, with high efficacy against variants that harbor resistance-associated substitutions. Pre-existing resistance mutations facilitated the selection of variants with high fitness.

1449 **Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice**
B. Pourcet, M. Zecchin, L. Ferri, J. Beauchamp, S. Sitaula, C. Billon, S. Delhaye, J. Vanhoutte, A. Mayeuf-Louchart, Q. Thorel, J. T. Haas, J. Eeckhoute, D. Dombrowicz, C. Duhem, A. Boulinguiez, S. Lancel, Y. Sebti, T. P. Burris, B. Staels, and H. M. Duez

Anti-inflammatory actions of the biological clock protein Rev-erbα may prevent the onset of fulminant hepatitis by regulating the NLRP3 inflammasome, and increase survival rates.

1465 **Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Activation of Hepatic Stellate Cells**
K. Du, J. Hyun, R. T. Premont, S. S. Choi, G. A. Michelotti, M. Swiderska-Syn, G. D. Dalton, E. Thelen, B. S. Rizi, Y. Jung, and A. M. Diehl

See editorial on page 1231.

Excessive growth of liver stellate cells that produce fibrosis is a major factor in the development of cirrhosis. This study demonstrates that stellate cells must break down glutamine to generate energy for growth and inhibiting that process blocks scarring.

Basic and Translational—Pancreas

1480 **JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice**
X. Song, S. Zhu, Y. Xie, J. Liu, L. Sun, D. Zeng, P. Wang, X. Ma, G. Kroemer, D. L. Bartlett, T. R. Billiar, M. T. Lotze, H. J. Zeh, R. Kang, and D. Tang

This study demonstrates that induction of alkaliptosis by agents such as JTC801 may represent a new therapeutic avenue for patients with pancreatic adenocarcinoma.

1494 **Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice**
P. He, J. W. Yang, V. W. Yang, and A. B. Bialkowska

Krüppel-like factor 5, a transcription factor overexpressed in pancreatic ductal adenocarcinoma, promotes acinar-to-ductal metaplasia, formation of pancreatic intraepithelial neoplasia, and tumor growth in genetic engineered mouse models.

1509 **Loss of *Pten* and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice**
J. L. Kopp, C. L. Dubois, D. F. Schaeffer, A. Samani, F. Taghizadeh, R. W. Cowan, A. D. Rhim, B. L. Stiles, M. Valasek, and M. Sander

Loss of the tumor suppressor Pten in mouse pancreatic ductal cells results in the formation of intraductal papillary mucinous neoplasia that recapitulates several aspects of human pancreatic disease, including spontaneous mutations in the oncogene Kras.

1524 **Galectin-3 Mediates Tumor Cell–Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling**
W. Zhao, J. A. Ajani, G. Sushovan, N. Ochi, R. Hwang, M. Hafley, R. L. Johnson, R. S. Bresalier, C. D. Logsdon, Z. Zhang, and S. Song

GAL3 activates PSC cells to produce inflammatory cytokines via ITGB1signaling to ILK and activation of NF-kB. Inhibition of this pathway reduced growth and metastases of pancreatic orthotopic tumors in mice.

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

e18 **Exam 1: Virtual Endoscopy Based on 3-Dimensional Reconstruction of Histopathology Features of Endoscopic Resection Specimens**

e20 **Exam 2: Two Types of Gastric Cancer Caused by the Same Underlying Condition**

e21 **Exam 3: No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication**

e22 **Exam 4: Increasing Rates of Surgery for Patients With Non-Malignant Colorectal Polyps in the United States**

SELECTED SUMMARIES

1538 **Overall Mortality and Pancreatic Cancer Mortality Among Patients With Pancreatic Cystic Neoplasms**
G. Anand, F. Youssef, and S. Gupta

1539 **Histologic Criteria to Define Irritable Bowel Syndrome: Within the Realms of Possibility?**
R. Sood and A. C. Ford

1541 **Primary Endoscopic Therapy Should be Preferred Over Surgery for Patients With Infected Pancreatic Necrosis**
D. G. Adler

CORRESPONDENCE

1543 **High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome**
L. Paleari, J. Burhenne, J. Weiss, S. Foersch, W. Roth, A. Parodi, M. Gnant, T. Bachleitner-Hofmann, D. Scherer, C. M. Ulrich, B. Stabuc, M. Puntoni, G. Coccia, M. Petrera, W.-E. Haefeli, and A. Decensi

1545 **Colon Cancer Survival and Statins: What More Evidence Do We Need?**
M. Bifulco and P. Gazzerro

1546 **Biomarkers for Nonalcoholic Steatohepatitis**
T. I. Ber and Y. Ilan

1546 **Reply**
Y. A. Patel, A. J. Sanyal, and V. Miller, and On behalf of the Liver Forum's Data Standardization Working Group

1547 **Low FODMAP Diet for IBS**
R. M. Craig

1548 **Reply**
H. M. Staudacher and K. Whelan

1549 **Risk of Hepatocellular Carcinoma After Cure of Hepatitis C Virus**
A. Ponzetto and N. Figura

1549 **Nonalcoholic Fatty Liver Disease in Alcohol Users: An Oxymoron?**
A. Braillon

1550 **Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response**
M. Mandorfer, T. Reiberger, and M. Peck-Radosavljevic

1551 **The Elevation of Hepatic Venous Pressure Gradient After Sustained Virologic Response in Hepatitis C Virus-Related Cirrhosis**
G.-H. Lo

1551 **Reply**
S. Lens, X. Forns, and J. C. García-Pagán

TABLE OF CONTENTS

1552 **New Insights for Controversial Issues of miR-122 in Hepatic Lipid Metabolism**
H.-H. Chung

1553 **Reply**
C. Chai, E. Galun, and H. Giladi